Group B Strep Screening Test

You are here

Group B Strep Screening Test

Pregnant women in Australia are routinely offered a screening test for Group B Streptococcus (GBS). GBS is commonly found in the gastrointestinal tract of men and women and colonises the vagina in approximately 15% to 30% of women. The danger to babies is that GBS bacteria is able to make microscopic holes in the amniotic sac, enabling it to reach the amniotic fluid and infect the baby.

GBS is the most common cause of overwhelming sepsis in newborn babies, causing pneumonia and meningitis with an incidence of 1 per 1,000 live births. GBS carriage is treated at the onset of labour using intravenous antibiotics. This course of treatment reduces the occurrence of early GBS infection for 1 in 25 babies, but does not have any effect on neonatal deaths from infection.

What is Group B Streptococcal Infection?

80% of infections are early onset, most of which are observable at or immediately after birth. 18% of premature babies with early onset GBS infection die and 6% of babies born at full term die. Babies that survive, particularly those who have meningitis, may have long-term problems, such as hearing (5%) or vision loss or learning disabilities. Late onset of GBS infection occurs between 7 and 90 days after the birth, with the baby acquiring infection at a later stage.

Screening of pregnant women for GBS carriage is offered routinely in Australia, though not in all developed countries.

What does the screening test involve?

It is offered as close to the birth as possible, usually between 35 and 37 weeks’ gestation. A swab of the vagina is performed either by the woman herself or by her caregiver, and sent to pathology laboratories for analysis. Swabs taken at this time are effective in predicting whether or not there will be GBS carriage during labour.

How is GBS treated?

GBS carriage is not treated during pregnancy, but at the onset of labour using intravenous antibiotics, ideally at least 4 hours prior to the birth and 4 hourly after the first dose.

Advantages of screening and treatment

The administration of intravenous antibiotics in labour for women who are GBS carriers, reduces the occurrence of early GBS infection for 1 in 25 babies, though the research is over 20 years old and of poor quality. Antibiotic treatment does not have any effect on neonatal deaths from infection.

Disadvantages of screening and treatment

  • Very few of the women in labour who are GBS positive give birth to babies who are infected with GBS.
  • A systematic review of the best research into antibiotics given in labour for the reduction of GBS infection in babies, found that the treatment did not have any effect on neonatal deaths from infection (Ohlsson et al. 2013 link).
  • Antibiotics can have harmful effects such as severe maternal allergic reactions, increase in drug-resistant organisms and exposure of newborn infants to resistant bacteria, and postnatal maternal and neonatal yeast infections.
  • If a woman's waters break before labour begins and she is known to be GBS+ some hospitals may recommend immediate induction of labour, and may recommend placing a time limit on the labour.
  • A woman planning to give birth at home may need to change her birth place if she wishes to opt to receive antibiotics during labour.


  • There is some evidence that intramuscular antibiotic treatment may be effective in preventing the communication of infection to the baby, but this is limited.
  • Not all caregivers offer routine screening for GBS. Some only recommend treating women who have recognised risk factors for early-onset GBS disease. These risk factors are: maternal fever, prolonged rupture of membranes, prolonged labour, prematurity and low birth weight, a previous baby affected by GBS disease, being a known carrier of GBS during the current pregnancy, GBS urine infection during the current pregnancy, severe changes in the baby’s heart rate during the first stage of labour, and gestational diabetes




The National Institute of Health and Clinical Excellence (NICE) recommendation:

No routine antenatal GBS screening

Due to the fact that the evidence of its clinical and cost-effectiveness continues to remain uncertain (NICE 2008:29 link).